Looking to publish in Neuro-oncology Advances? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Try Livewrite NowNeuro-Oncology Advances is an open access interdisciplinary journal covering basic, applied, and clinical investigations in all research areas relating to cancers of the central nervous system.
Looking to publish in Neuro-oncology Advances? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Try Livewrite NowSubmission Instructions
Neuro-oncology Advances accepts the following article types. Click on an article type to view submission instructions.
Basic And Translational Investigations
Clinical Investigations
Metadata Analyses
Systematic Reviews
Review Articles
Clinical Trial Reports
Brief Communications
Molecular Tumor Board Case Reports
Recent Publications
A New Method for Optimal Placement of Tumor Treating Fields Electrodes
Konstantin Weise, Nikola Mikic, Fang Cao, Eric T Wong, Thomas R Knösche, Axel Thielscher, Anders Rosendal Korshøj
Combination of KRASG12C targeted adagrasib with anti-PD-1 immune-checkpoint inhibitor to improve overall survival and prevent recurrence in preclinical models of brain metastasis
Consuelo Torrini, Naema Nayyar, Gregory R Wojtkiewicz, Anita Giobbie-Hurder, Magali A de Sauvage, Christian Migliarese, Elizabeth J Summers, Nazanin Ijad, Erika Yamazawa, Britney S Zhang, Emily M Sullivan, Varun Sasisekharan, Leland G Richardson, Braxton M Marion, Peter Olson, Hiroaki Wakimoto, Priscilla K Brastianos
Possible involvement of genome-wide near-haploidy and MEN1 mutation in the molecular pathogenesis of pituitary carcinoma: analysis by whole exome sequencing
Satoru Kida, Takuma Nakashima, Satoshi Baba, Shinichiro Koizumi, Miho Yamashita, Sumihito Nobusawa, Chie Inomoto, Hiroyoshi Kino, Eiichi Ishikawa, Kazuhito Takeuchi, Tetsuya Nagatani, Ryuta Saito, Shingo Fujio, Ryosuke Hanaya, Joji Ishida, Shota Tanaka, Isao Date, Yasuyuki Kinoshita, Akira Taguchi, Yoshitaka Narita, Hiromichi Suzuki, Kazuhiko Kurozumi
Pharmacologic Inhibition of RBBP4/p300-mediated Homologous Recombination Activity Enhances Glioblastoma Sensitivity to Temozolomide
Josephine A Mapunda, Daniel J Laverty, Faisal Aziz, An Le, Junita Sangare, Lin Zhang, Zachary D Nagel, Jarrod B French, Jann N Sarkaria, Gaspar J Kitange
Explainable ML/AI Model for Estimating Postoperative Survival in Renal Cell Carcinoma Brain Metastasis Patients
Zuhair Majeed, Semiha Ozgul, Peng Li, Dima Suki, Yusuf Acikgoz, Eric Jonasch, Sherise Desiree Ferguson, Merve Hasanov, Elshad Hasanov
Frequently asked questions
How long does it take to publish?
Single-blind peer review; reviewers are asked to provide feedback within 2 weeks. Appeals or rebuttals must be submitted within 4 weeks of the decision. Page proofs should be returned within 2 working days. Accepted manuscripts are published online as soon as possible after acceptance through Advance Access, with daily updates.
Reformat to Neuro-oncology Advances using Livewrite PremiumIs a cover letter required?
A cover letter addressed to the editor should be uploaded as a separate Word (.doc or .docx) file. It should declare whether the manuscript or any part of it has been previously published or submitted concurrently elsewhere, state that all authors have seen and approved the submitted version, disclose use of AI if applicable, and state that neither the submitted paper nor any similar paper has been or will be submitted to or published in any other source.
Reformat to Neuro-oncology Advances using Livewrite PremiumWhat are the publication costs?
There is usually an Article Processing Charge (APC) for publication in fully open access journals, and hybrid journals usually charge an APC for gold open access publication.
Reformat to Neuro-oncology Advances using Livewrite Premium